HPV circulating tumour DNA to guide cervical cancer therapy
Because cervical tumours carry viral DNA that normal cells do not, a blood test for HPV DNA is a near-perfect tumour marker for tracking response and relapse.
Plasma HPV ctDNA (droplet digital PCR or NGS) is detectable in most locally advanced cases, falls with chemoradiation, and predicts relapse months before imaging (Cabel, Han, and others). Analogous to HPV ctDNA in oropharyngeal cancer, where commercial assays exist.
Pages like this
not linked directly; found by shared links- PersonAsh A. Alizadeh
Shares Circulating tumour DNA (ctDNA), Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
- PairingPD-1 blockade + chemoradiation (locally advanced cervical cancer)
Shares KEYNOTE-A18 / ENGOT-cx11 / GOG-3047, Cervical cancer, Pembrolizumab.
- IdeaTake the blood test, and give the drug, at the right time of day
Shares Circulating tumour DNA (ctDNA), Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
- PersonSarah-Jane Dawson
Shares Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
- PersonMaximilian Diehn
Shares Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
- IdeaBank yearly blood from cancer survivors so future tests can be validated
Shares Circulating tumour DNA (ctDNA), Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
- IdeaCertified reference samples to benchmark every tumour-DNA blood test
Shares Circulating tumour DNA (ctDNA), Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
- IdeaCirculating tumour cell clearance as the phase 2 gate for anti-metastatic drugs
Shares Circulating tumour DNA (ctDNA), Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).